Market Cap 574.98M
Revenue (ttm) 0.00
Net Income (ttm) -99.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 531,873
Avg Vol 537,870
Day's Range N/A - N/A
Shares Out 94.88M
Stochastic %K 34%
Beta 0.24
Analysts Strong Sell
Price Target $15.86

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33...

Industry: Biotechnology
Sector: Healthcare
Phone: 702 825 9872
Website: zurabio.com
Address:
1489 W. Warm Springs Road, Suite 110, Henderson, United States
Breck100
Breck100 Apr. 6 at 3:58 PM
$ZURA Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Apr 01, 2026, 07:37 AM Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Zura Bio today and set a price target of $26.00.
0 · Reply
FairytalePalaceTrades
FairytalePalaceTrades Mar. 31 at 11:37 PM
$ZURA jsut hold it will pay
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:32 AM
$ZURA is also showing clearly defined Ellitt Waves. Wave 5 was completed 7.44. The next majot support line which I believe wave C will hit is the equilibrium of 4.30. There appears to be strong support zround 5.00. That should be the bottom of wave A and the start of a small bullish wave B.
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:24 AM
$ZURA Bias: Neutral → Slight Bullish Trend: Attempting base / higher-lows forming RSI: 55 Key Levels: Support: 5.7 Resistance: 6.2 Alpha Take: Higher lows + RSI strength 6.2 break = continuation setup Lose 5.7 = invalidation
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:20 AM
$ZURA 4hr - Really nice looking chart... lower blue UP arrow pointing to where price bounced perfectly off the lower Trend Line back in mid Jan 2026 around 4.70 area & ran ALL the way up to 7.20. Upper blue arrow pointing to where it hit resistance at that upper Trend Line around 7.20 & is now pulling back. Currently @ 5.92 testing the midpoint of that channel. All MA's ( pink 10ma, yellow 30ma ) starting to flatten & curl, 200ema ( salmon ) way below still rising. 5.30 is the next S / R Lvl below, that lower Trend Line around 5.10 to 5.30 would be the ideal bounce zone if this continues lower. Hold 5.30 & this sets up for another push toward 6.40 to 7.20 range. Watch that lower Trend Line
0 · Reply
Breck100
Breck100 Mar. 18 at 7:35 PM
$ZURA 3/17/26 Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 824,078 shares of the company's stock, valued at approximately $3,568,000. Boothbay Fund Management LLC owned approximately 1.27% of Zura Bio as of its most recent filing with the Securities and Exchange Commission.
0 · Reply
Pepe_sanchez89
Pepe_sanchez89 Mar. 10 at 2:47 PM
$ZURA anybody in here?
1 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$ZURA Warrant-related disclosures this morning
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:47 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:40 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
Latest News on ZURA
Zura Bio to Participate in Upcoming Investor Conferences

Mar 2, 2026, 6:30 AM EST - 5 weeks ago

Zura Bio to Participate in Upcoming Investor Conferences


Zura Bio Reports Business Updates and Outlook for 2026

Jan 12, 2026, 6:30 AM EST - 3 months ago

Zura Bio Reports Business Updates and Outlook for 2026


Zura Bio Announces Chief Financial Officer Transition

Jul 1, 2025, 6:30 AM EDT - 10 months ago

Zura Bio Announces Chief Financial Officer Transition


Zura Bio to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 6:30 AM EDT - 11 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference


Zura Bio Announces Participation in June Investor Conferences

May 29, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Participation in June Investor Conferences


Zura Bio Announces Robert Lisicki as CEO and Director

Apr 8, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Robert Lisicki as CEO and Director


Zura Bio Announces Participation at March Conferences

Mar 4, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at March Conferences


Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 6:30 AM EDT - 3 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes


Breck100
Breck100 Apr. 6 at 3:58 PM
$ZURA Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Apr 01, 2026, 07:37 AM Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Zura Bio today and set a price target of $26.00.
0 · Reply
FairytalePalaceTrades
FairytalePalaceTrades Mar. 31 at 11:37 PM
$ZURA jsut hold it will pay
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:32 AM
$ZURA is also showing clearly defined Ellitt Waves. Wave 5 was completed 7.44. The next majot support line which I believe wave C will hit is the equilibrium of 4.30. There appears to be strong support zround 5.00. That should be the bottom of wave A and the start of a small bullish wave B.
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:24 AM
$ZURA Bias: Neutral → Slight Bullish Trend: Attempting base / higher-lows forming RSI: 55 Key Levels: Support: 5.7 Resistance: 6.2 Alpha Take: Higher lows + RSI strength 6.2 break = continuation setup Lose 5.7 = invalidation
0 · Reply
BarbaraVeachi
BarbaraVeachi Mar. 30 at 5:20 AM
$ZURA 4hr - Really nice looking chart... lower blue UP arrow pointing to where price bounced perfectly off the lower Trend Line back in mid Jan 2026 around 4.70 area & ran ALL the way up to 7.20. Upper blue arrow pointing to where it hit resistance at that upper Trend Line around 7.20 & is now pulling back. Currently @ 5.92 testing the midpoint of that channel. All MA's ( pink 10ma, yellow 30ma ) starting to flatten & curl, 200ema ( salmon ) way below still rising. 5.30 is the next S / R Lvl below, that lower Trend Line around 5.10 to 5.30 would be the ideal bounce zone if this continues lower. Hold 5.30 & this sets up for another push toward 6.40 to 7.20 range. Watch that lower Trend Line
0 · Reply
Breck100
Breck100 Mar. 18 at 7:35 PM
$ZURA 3/17/26 Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 824,078 shares of the company's stock, valued at approximately $3,568,000. Boothbay Fund Management LLC owned approximately 1.27% of Zura Bio as of its most recent filing with the Securities and Exchange Commission.
0 · Reply
Pepe_sanchez89
Pepe_sanchez89 Mar. 10 at 2:47 PM
$ZURA anybody in here?
1 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$ZURA Warrant-related disclosures this morning
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:47 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:40 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
StockConsultant
StockConsultant Mar. 3 at 2:22 PM
$ZURA Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?ZURA
0 · Reply
Emma_Brownnn
Emma_Brownnn Mar. 2 at 4:02 PM
$ZURA 4hr - 7.85 - 10$ can be long targets if momentum continues, mostly 7.85$ & likely rejection down to the blue arrow, if the light blue Trend Line fails to hold then watch for the Lower Trend to be tested @ the blue arrow towards 3.50$ if that 4.75$ area cannot hold after the Trend
0 · Reply
trading_insight
trading_insight Mar. 2 at 4:01 PM
$ZURA - Higher Low Attempt Structure: Forming higher lows off 6.00; holding 6.50 area. RSI: 50 (balanced). MACD: Curling positive. Key Levels Resistance: 6.80 → 7.10 Support: 6.30 → 6.00 Break Trigger: 7.10 Alpha: Constructive above 6.30. 7.10 clears supply for momentum push.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA From a geopolitical lens, small-cap biotech is relatively insulated from oil shocks and Middle East escalation compared to cyclicals, though in a broad risk-off event liquidity can still pressure secondaries; Alpha scenario: post-offering stabilization and risk rotation into defensives drive a push back toward supply. Beta scenario: escalation-driven equity weakness pulls price back toward the lower demand band despite improved cash runway.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA is trading near $6.60 after pricing and closing its $134.6M–$144M public offering at $6.25, which explains the recent supply pressure and rejection near the $7.20 supply zone, while strong demand remains layered around $6.20–$6.35; technically, holding above the offering price is constructive and suggests absorption, with upside toward $7.00–$7.20 if buyers regain control, but a break below $6.20 risks a fade toward $5.90. Fundamentally, the capital raise materially strengthens the balance sheet and reduces near-term financing overhang, which is positive longer term despite dilution.
0 · Reply
AAUS1
AAUS1 Mar. 1 at 2:04 PM
$ZURA scratching my head , really lost
0 · Reply
focafoca99
focafoca99 Feb. 27 at 1:35 PM
$ZURA offering done. What’s next — rally or pullback?
0 · Reply
briefingcom
briefingcom Feb. 25 at 12:55 PM
$ZURA: Zura Bio Limited (-4.3%) announces proposed public offering of Class A Ordinary Shares
1 · Reply
JeffreyCress
JeffreyCress Feb. 24 at 9:06 PM
$ZURA offering…
1 · Reply
Quantumup
Quantumup Feb. 24 at 2:55 PM
TD Cowen reiterated $AVTX at a Buy rating and said, Risk/Reward Skewed To Significant Upside For AVTX-009 Phase Il In Large HS Oppy $ABBV $MLTX $ZURA Here's what else TD Cowen had to say in its note to investors: https://x.com/Quantumup1/status/2026309287077658777?s=20
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 2:29 PM
$ZURA Zura Bio stock, watch for a bull flag breakout at https://stockconsultant.com/?ZURA
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 4:49 PM
$ZURA Current Stock Price: $6.54 Contracts to trade: $7.5 ZURA Mar 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply